| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| MousePheno | abnormal mammary gland epithelium physiology | 7.21e-05 | 23 | 8 | 2 | MP:0010172 | |
| Domain | GAGE | GAGE12H GAGE2A GAGE1 GAGE4 GAGE13 GAGE12F GAGE12I GAGE2E GAGE12J | 1.58e-22 | 24 | 19 | 9 | PF05831 |
| Domain | GAGE_fam | GAGE12H GAGE2A GAGE1 GAGE4 GAGE13 GAGE12F GAGE12I GAGE2E GAGE12J | 2.46e-22 | 25 | 19 | 9 | IPR008625 |
| Domain | GAGE | 7.08e-12 | 19 | 19 | 5 | SM01379 | |
| Domain | GAGE | 7.08e-12 | 19 | 19 | 5 | IPR031320 | |
| Domain | fn3 | 1.16e-02 | 162 | 19 | 2 | PF00041 | |
| Domain | FN3 | 1.49e-02 | 185 | 19 | 2 | SM00060 | |
| Domain | FN3 | 1.71e-02 | 199 | 19 | 2 | PS50853 | |
| Domain | FN3_dom | 1.88e-02 | 209 | 19 | 2 | IPR003961 | |
| Pubmed | An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. | GAGE2B GAGE10 GAGE12H GAGE1 GAGE4 GAGE13 GAGE7 GAGE12F GAGE12I GAGE2E GAGE12J | 1.01e-31 | 20 | 23 | 11 | 18179644 |
| Pubmed | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. | GAGE2B GAGE10 GAGE1 GAGE13 GAGE7 GAGE12G GAGE12F GAGE12I GAGE2E GAGE12J | 1.65e-19 | 119 | 23 | 10 | 28625976 |
| Pubmed | 9.98e-15 | 9 | 23 | 5 | 7544395 | ||
| Pubmed | 2.00e-14 | 10 | 23 | 5 | 9651357 | ||
| Pubmed | Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. | 3.66e-14 | 11 | 23 | 5 | 10397259 | |
| Pubmed | GAGE2B GAGE10 GAGE12H GAGE2A GAGE13 GAGE7 GAGE12I GAGE2E GAGE12J | 2.66e-12 | 407 | 23 | 9 | 15772651 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 30871606 | ||
| Interaction | FLT3 interactions | GAGE2B GAGE10 GAGE1 GAGE13 GAGE7 GAGE12G GAGE12F GAGE12I GAGE2E NUP205 GAGE12J | 1.88e-15 | 318 | 20 | 11 | int:FLT3 |
| Interaction | GMCL1 interactions | 1.13e-12 | 154 | 20 | 8 | int:GMCL1 | |
| Interaction | GAGE12G interactions | 1.96e-05 | 7 | 20 | 2 | int:GAGE12G | |
| Interaction | EXOC3L2 interactions | 8.45e-05 | 14 | 20 | 2 | int:EXOC3L2 | |
| Cytoband | Xp11.23 | GAGE2B GAGE12H GAGE2A GAGE1 GAGE13 GAGE12G GAGE12F GAGE12I GAGE2E GAGE12J | 9.88e-22 | 95 | 23 | 10 | Xp11.23 |
| Cytoband | Ensembl 112 genes in cytogenetic band chrXp11 | GAGE10 GAGE12H GAGE2A GAGE1 GAGE13 GAGE12G GAGE12F GAGE2E GAGE12J | 1.14e-13 | 377 | 23 | 9 | chrXp11 |
| Cytoband | Xp11.4-p11.2 | 3.60e-06 | 6 | 23 | 2 | Xp11.4-p11.2 | |
| GeneFamily | Fibronectin type III domain containing | 1.14e-03 | 160 | 6 | 2 | 555 | |
| Coexpression | SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER | 2.98e-06 | 47 | 16 | 3 | M11213 | |
| Coexpression | RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP | 4.17e-05 | 16 | 16 | 2 | M16309 | |
| Coexpression | DALESSIO_TSA_RESPONSE | 1.13e-04 | 26 | 16 | 2 | M2340 | |
| Coexpression | ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN | 1.30e-04 | 873 | 16 | 5 | M16009 | |
| Coexpression | GSE411_100MIN_VS_400MIN_IL6_STIM_SOCS3_KO_MACROPHAGE_DN | 2.28e-04 | 200 | 16 | 3 | M5995 | |
| Coexpression | SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2 | 3.72e-04 | 47 | 16 | 2 | M9702 | |
| Coexpression | SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER | 3.72e-04 | 47 | 16 | 2 | M5542 | |
| Drug | Finish | 7.28e-07 | 23 | 18 | 3 | CID000086133 | |
| Drug | 1ct8 | 9.07e-06 | 173 | 18 | 4 | CID000444888 | |
| Drug | IPEM | 1.24e-05 | 7 | 18 | 2 | CID000126238 | |
| Drug | AC1Q6AQ7 | 1.26e-05 | 188 | 18 | 4 | CID000005515 | |
| Drug | 2-methyl-2,4-pentanediol | 1.48e-05 | 196 | 18 | 4 | CID000007870 | |
| Drug | hexadecanol | 2.39e-05 | 72 | 18 | 3 | CID000002682 | |
| Drug | 4-thiouracil | 3.88e-05 | 12 | 18 | 2 | CID002734394 | |
| Drug | 4-META | 6.16e-05 | 15 | 18 | 2 | CID000051027 | |
| Drug | 1bn3 | 7.97e-05 | 17 | 18 | 2 | CID000001514 | |
| Drug | 1bnn | 1.00e-04 | 19 | 18 | 2 | CID000001604 | |
| Drug | indene | 1.10e-04 | 120 | 18 | 3 | CID000007219 | |
| Drug | dialuminum | 1.75e-04 | 25 | 18 | 2 | CID006857644 | |
| Drug | AC1L9KOK | 2.53e-04 | 30 | 18 | 2 | CID000447287 | |
| Drug | Al5300 | 2.71e-04 | 31 | 18 | 2 | CID000001611 | |
| Drug | t-MA | 2.89e-04 | 32 | 18 | 2 | CID000011089 | |
| Drug | AC1O5D5R | 3.07e-04 | 33 | 18 | 2 | CID006482240 | |
| Drug | hafnium | 4.30e-04 | 39 | 18 | 2 | CID000023986 | |
| Disease | Carcinoma, Granular Cell | 8.23e-04 | 116 | 11 | 2 | C0205644 | |
| Disease | Adenocarcinoma, Tubular | 8.23e-04 | 116 | 11 | 2 | C0205645 | |
| Disease | Adenocarcinoma, Oxyphilic | 8.23e-04 | 116 | 11 | 2 | C0205642 | |
| Disease | Carcinoma, Cribriform | 8.23e-04 | 116 | 11 | 2 | C0205643 | |
| Disease | Adenocarcinoma, Basal Cell | 8.23e-04 | 116 | 11 | 2 | C0205641 | |
| Disease | Adenocarcinoma | 8.23e-04 | 116 | 11 | 2 | C0001418 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| MMEPPKPEPELQRFY | 1 | Q9NVE4 | |
| GMRDPPMFIPTPVDR | 1601 | Q92621 | |
| RYVQPPEMIGPMRPE | 16 | P0DTW1 | |
| RYVQPPEMIGPMRPE | 16 | O76087 | |
| RYVQPPEMIGPMRPE | 16 | Q4V326 | |
| YVEPPEMIGPMRPEQ | 16 | Q9UEU5 | |
| YVEPPEMIGPMRPEQ | 16 | Q6NT46 | |
| MAEMDPVAEFPQPPG | 1 | Q9HAB8 | |
| MIVYPMGLPPYDPIR | 151 | P57076 | |
| RYVQPPEMIGPMRPE | 16 | A1L429 | |
| RYVQPPEMIGPMRPE | 16 | P0CL80 | |
| RYVQPPEMIGPMRPE | 16 | P0CL81 | |
| RYVQPPEMIGPMRPE | 16 | A6NDE8 | |
| RYVQPPEMIGPMRPE | 16 | P0CL82 | |
| PYVQPPEMIGPMRPE | 16 | A6NER3 | |
| YVEPPEMIGPMLPEQ | 16 | A6NGK3 | |
| MEPQPPNVPESEMKY | 1226 | Q8N3K9 | |
| RYVEPPEMIGPMRPE | 16 | Q4V321 | |
| VPMYTGPESRQEVPM | 461 | Q96EK7 | |
| RYVQPPEMIGPMRPE | 16 | P0DSO3 | |
| YVEPPEMIGPMRPEQ | 16 | Q13066 | |
| SMQLGPDMVPQVYPP | 681 | P42226 | |
| DQEMPCPVPPARMYL | 1211 | Q9Y6N7 | |
| MIRGFEAPMAENPPP | 1 | Q7RTV3 | |
| PMDGPPVRIAYMLVV | 226 | Q9H1B5 |